Skip to main content
Erschienen in: Clinical & Experimental Metastasis 3/2012

01.03.2012 | Research Paper

Generation and characterization of orthotopic murine models for endometrial cancer

verfasst von: Silvia Cabrera, Marta Llauradó, Josep Castellví, Yolanda Fernandez, Francesc Alameda, Eva Colás, Anna Ruiz, Andreas Doll, Simó Schwartz Jr., Ramon Carreras, Jordi Xercavins, Miguel Abal, Antonio Gil-Moreno, Jaume Reventós

Erschienen in: Clinical & Experimental Metastasis | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

We describe the generation of two orthotopic murine models for endometrial cancer (EC).The first model is generated from endometrial Hec-1A cancer cells transfected with luciferase and injected directly into the uterus of female mice. This model allows a follow-up with bioluminescence imaging (BLI) along the experiment and generates abdominal dissemination and lymphatic and hematogenous metastases in high percentages, also detectables with BLI. The dissemination pattern of this model imitates the advanced stages of EC in patients, and its molecular profile corresponds to aggressive type 2 EC (p53 positive, hormone receptors negative, high percentage of Ki67 positive cells). The second model is derived from endometrioid human tissue collected from surgical pieces. By injecting this tissue inside the uterine cavity of a mouse we obtain orthotopic growth with pelvic dissemination and lymph node metastasis. The molecular pattern observed in human type 1 endometrioid EC (p53 negative, low Ki67 index, presence of hormone receptors) is conserved after the murine growth in orthotopic tumor and metastases. This model supposes a singular pre-clinical tool to study therapeutic agents, though it mimics clinical and molecular behavior of endometrioid EC, which is the most common histology in the patient.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Baekelandt MM, Castiglione M (2009) ESMO Guidelines Working group.Endometrial carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20(4):iv29–iv31CrossRef Baekelandt MM, Castiglione M (2009) ESMO Guidelines Working group.Endometrial carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20(4):iv29–iv31CrossRef
2.
Zurück zum Zitat Homesley HD, Filiaci V, Gibbons SK et al (2009) A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with our without paclitaxel: a Gynecologic Oncology Group study. Gynecol Oncol 112:543–552PubMedCrossRef Homesley HD, Filiaci V, Gibbons SK et al (2009) A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with our without paclitaxel: a Gynecologic Oncology Group study. Gynecol Oncol 112:543–552PubMedCrossRef
3.
Zurück zum Zitat Gehrig PA, Bae-Jump VL (2010) Promising novel therapies for the treatment of endometrial cancer. Gynecol Oncol 116:187–194PubMedCrossRef Gehrig PA, Bae-Jump VL (2010) Promising novel therapies for the treatment of endometrial cancer. Gynecol Oncol 116:187–194PubMedCrossRef
4.
Zurück zum Zitat Bokhman JV (1983) Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 15(1):10–17PubMedCrossRef Bokhman JV (1983) Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 15(1):10–17PubMedCrossRef
5.
Zurück zum Zitat Hecht J, Mutter GL (2006) Molecular and pathologic aspects of endometrial carcinogenesis. J Clin Oncol 24(29):4783–4791PubMedCrossRef Hecht J, Mutter GL (2006) Molecular and pathologic aspects of endometrial carcinogenesis. J Clin Oncol 24(29):4783–4791PubMedCrossRef
6.
Zurück zum Zitat Lax SF, Kendall B, Tashiro H et al (2000) The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. Cancer 88(4):814–824PubMedCrossRef Lax SF, Kendall B, Tashiro H et al (2000) The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. Cancer 88(4):814–824PubMedCrossRef
7.
Zurück zum Zitat Doll A, Abal M, Rigau M et al (2008) Novel molecular profiles of endometrial cancer-new light through old windows. J Steroid Biochem Mol Biol 108(3–5):221–229PubMedCrossRef Doll A, Abal M, Rigau M et al (2008) Novel molecular profiles of endometrial cancer-new light through old windows. J Steroid Biochem Mol Biol 108(3–5):221–229PubMedCrossRef
8.
Zurück zum Zitat Bansal N, Yendluri V, Robert M et al (2009) The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies. Cancer Control 16(1):8–13PubMed Bansal N, Yendluri V, Robert M et al (2009) The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies. Cancer Control 16(1):8–13PubMed
9.
Zurück zum Zitat Vardi JR, Tadros GH, Anselmo MT et al (1992) The value of exploratory laparotomy in patients with endometrial carcinoma according to the new International Federation of Gynecology and Obstetrics staging. Obstet Gynecol 80:204–208PubMed Vardi JR, Tadros GH, Anselmo MT et al (1992) The value of exploratory laparotomy in patients with endometrial carcinoma according to the new International Federation of Gynecology and Obstetrics staging. Obstet Gynecol 80:204–208PubMed
10.
Zurück zum Zitat Ballon SC, Berman ML, Donaldson RC et al (1979) Pulmonary metastases of endometrial carcinoma. Gynecol Oncol 7:56–65PubMedCrossRef Ballon SC, Berman ML, Donaldson RC et al (1979) Pulmonary metastases of endometrial carcinoma. Gynecol Oncol 7:56–65PubMedCrossRef
11.
Zurück zum Zitat Bouros D, Papadakis K, Siafakas N et al (1996) Natural history of patients with pulmonary metastases from uterine cancer. Cancer 78:441–447PubMedCrossRef Bouros D, Papadakis K, Siafakas N et al (1996) Natural history of patients with pulmonary metastases from uterine cancer. Cancer 78:441–447PubMedCrossRef
12.
Zurück zum Zitat Doll A, Gonzalez M, Abal M et al (2009) An orthotopic endometrial cancer mouse model demonstrates a role for RUNX1 in distant metastasis. Int. J Cancer 125:257–263 Doll A, Gonzalez M, Abal M et al (2009) An orthotopic endometrial cancer mouse model demonstrates a role for RUNX1 in distant metastasis. Int. J Cancer 125:257–263
13.
Zurück zum Zitat O’Neill K, Lyons SK, Gallagher WM et al (2010) Bioluminescent imaging: a critical tool in pre-clinical oncology research. J Pathol 220:317–327PubMed O’Neill K, Lyons SK, Gallagher WM et al (2010) Bioluminescent imaging: a critical tool in pre-clinical oncology research. J Pathol 220:317–327PubMed
14.
Zurück zum Zitat Zhang C, Yan Z, Arango ME et al (2009) Advancing bioluminescence imaging technology for the evaluation of anticancer agents in the MDA-MB-435-HAL-Luc mammary fat pad and subrenal capsule tumor models. Clin Cancer Res 15:238–246PubMedCrossRef Zhang C, Yan Z, Arango ME et al (2009) Advancing bioluminescence imaging technology for the evaluation of anticancer agents in the MDA-MB-435-HAL-Luc mammary fat pad and subrenal capsule tumor models. Clin Cancer Res 15:238–246PubMedCrossRef
15.
Zurück zum Zitat Du X, Jiang T, Sheng X et al (2009) Inhibition of osteopontin suppresses in vitro and in vivo angiogenesis in endometrial cancer. Gynecol Oncol 115:371–376PubMedCrossRef Du X, Jiang T, Sheng X et al (2009) Inhibition of osteopontin suppresses in vitro and in vivo angiogenesis in endometrial cancer. Gynecol Oncol 115:371–376PubMedCrossRef
16.
Zurück zum Zitat Dai D, Holmes AM, Nguyen T et al (2005) A potential synergistic anticancer effect of paclitaxel and amifostine on endometrial cancer. Cancer Res 65(20):9517–9524PubMedCrossRef Dai D, Holmes AM, Nguyen T et al (2005) A potential synergistic anticancer effect of paclitaxel and amifostine on endometrial cancer. Cancer Res 65(20):9517–9524PubMedCrossRef
17.
Zurück zum Zitat Saidi SA, Holland CM, Charnock-Jones S et al (2006) In vitro and in vivo effects of the PPAR-alpha agonists fenofibrate and retinoic acid in endometrial cancer. Mol Cancer 5:13PubMedCrossRef Saidi SA, Holland CM, Charnock-Jones S et al (2006) In vitro and in vivo effects of the PPAR-alpha agonists fenofibrate and retinoic acid in endometrial cancer. Mol Cancer 5:13PubMedCrossRef
18.
Zurück zum Zitat Wallace AE, Sales KJ, Catalano RD et al (2009) Prostaglandin F2A-F-prostanoid receptor signaling promotes neutrophil chemotaxis via chemokine (C-X-C Motif) Ligand 1 in endometrial adenocarcinoma. Cancer Res 69:5726–5733PubMedCrossRef Wallace AE, Sales KJ, Catalano RD et al (2009) Prostaglandin F2A-F-prostanoid receptor signaling promotes neutrophil chemotaxis via chemokine (C-X-C Motif) Ligand 1 in endometrial adenocarcinoma. Cancer Res 69:5726–5733PubMedCrossRef
19.
Zurück zum Zitat Fidler IJ (1991) Orthotopic implantation of human colon carcinomas into nude mice provides a valuable model for the biology and therapy of metastasis. Cancer Metastasis Rev 10:229–243PubMedCrossRef Fidler IJ (1991) Orthotopic implantation of human colon carcinomas into nude mice provides a valuable model for the biology and therapy of metastasis. Cancer Metastasis Rev 10:229–243PubMedCrossRef
20.
Zurück zum Zitat John CM, Leffler H, Kahl-Knutsson B et al (2003) Truncated galectin-3 inhibits tumor growth and metastasis in orthotopic nude mouse model of human breast cancer. Clin Cancer Res 9:2374–2383PubMed John CM, Leffler H, Kahl-Knutsson B et al (2003) Truncated galectin-3 inhibits tumor growth and metastasis in orthotopic nude mouse model of human breast cancer. Clin Cancer Res 9:2374–2383PubMed
21.
Zurück zum Zitat Chong L, Ruping Y, Jiancheng B et al (2006) Characterization of a novel transplantable orthotopic murine xenograft model of a human bladder transitional cell tumor (BIU-87). Cancer Biol Ther 5(4):394–398PubMedCrossRef Chong L, Ruping Y, Jiancheng B et al (2006) Characterization of a novel transplantable orthotopic murine xenograft model of a human bladder transitional cell tumor (BIU-87). Cancer Biol Ther 5(4):394–398PubMedCrossRef
22.
Zurück zum Zitat Report Meeting (2009) The new FIGO staging system for cancers of the vulva, cervix, endometrium and sarcomas. Gynecol Oncol 115:325–328CrossRef Report Meeting (2009) The new FIGO staging system for cancers of the vulva, cervix, endometrium and sarcomas. Gynecol Oncol 115:325–328CrossRef
23.
Zurück zum Zitat Kamat AA, Merritt WM, Coffey D et al (2007) Clinical and biological significance of vascular endothelial growth factor in endometrial cancer. Clin Cancer Res 13:7487–7495PubMedCrossRef Kamat AA, Merritt WM, Coffey D et al (2007) Clinical and biological significance of vascular endothelial growth factor in endometrial cancer. Clin Cancer Res 13:7487–7495PubMedCrossRef
24.
Zurück zum Zitat Lee JW, Stone RL, Lee SJ et al (2010) EphA2 targeted chemotherapy using an antibody drug conjugate in endometrial carcinoma. Cancer Res 16:2562–2570CrossRef Lee JW, Stone RL, Lee SJ et al (2010) EphA2 targeted chemotherapy using an antibody drug conjugate in endometrial carcinoma. Cancer Res 16:2562–2570CrossRef
25.
Zurück zum Zitat Takahashi K, Saga Y, Mizukami H et al (2009) Cetuximab inhibits growth, peritoneal dissemination, and lymph node and lung metastasis of endometrial cancer, and prolongs host survival. Int J Oncol 35:725–729PubMed Takahashi K, Saga Y, Mizukami H et al (2009) Cetuximab inhibits growth, peritoneal dissemination, and lymph node and lung metastasis of endometrial cancer, and prolongs host survival. Int J Oncol 35:725–729PubMed
Metadaten
Titel
Generation and characterization of orthotopic murine models for endometrial cancer
verfasst von
Silvia Cabrera
Marta Llauradó
Josep Castellví
Yolanda Fernandez
Francesc Alameda
Eva Colás
Anna Ruiz
Andreas Doll
Simó Schwartz Jr.
Ramon Carreras
Jordi Xercavins
Miguel Abal
Antonio Gil-Moreno
Jaume Reventós
Publikationsdatum
01.03.2012
Verlag
Springer Netherlands
Erschienen in
Clinical & Experimental Metastasis / Ausgabe 3/2012
Print ISSN: 0262-0898
Elektronische ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-011-9444-2

Weitere Artikel der Ausgabe 3/2012

Clinical & Experimental Metastasis 3/2012 Zur Ausgabe

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Klinik aktuell Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.